Evidence map›Paper›PMID 38306055›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology.

Brenda L Plassman, Cassie B Ford, Valerie A Smith, Nicole DePasquale, James R Burke, Laura Korthauer, Brian R Ott, Emmanuelle Belanger, Megan E Shepherd-Banigan, Elyse Couch and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Brenda L PlassmanDepartment of Psychiatry and Behavioral Sciences, School of Medicine, Duke University, Durham, NC, USA.
Cassie B FordDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Valerie A SmithDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Nicole DePasqualeDepartment of Medicine, Division of General Internal Medicine, Duke University, Durham, NC, USA.
James R BurkeDepartment of Psychiatry and Behavioral Sciences, School of Medicine, Duke University, Durham, NC, USA.
Laura KorthauerDepartment of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA.
Brian R OttDepartment of Neurology, Alpert Medical School of Brown University, Providence, RI, USA.
Emmanuelle BelangerDepartment of Health Services Policy and Practice, School of Public Health, Brown University, Providence, RI, USA.
Megan E Shepherd-BaniganDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Elyse CouchDepartment of Health Services Policy and Practice, School of Public Health, Brown University, Providence, RI, USA.
Eric JutkowitzDepartment of Health Services Policy and Practice, School of Public Health, Brown University, Providence, RI, USA.
Emily C O'BrienDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Corinna SorensonDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Terrie T WetleDepartment of Health Services Policy and Practice, School of Public Health, Brown University, Providence, RI, USA.
Courtney H Van HoutvenDepartment of Population Health Sciences, Duke University, Durham, NC, USA.
Duke University · USBrown University · USDurham VA Medical Center · US

Funding

Caregivers' Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning CARE IDEASR01AG053934 · NIA · BROWN UNIVERSITY · PI WETLE, TERRIE FOX · 2017 to 2020
$4.5M
NIA NIH HHS R01 AG053934
6 · The paper itself

Abstract

backgroundElevated amyloid-β (Aβ) on positron emission tomography (PET) scan is used to aid diagnosis of Alzheimer's disease (AD), but many prior studies have focused on patients with a typical AD phenotype such as amnestic mild cognitive impairment (MCI). Little is known about whether elevated Aβ on PET scan predicts rate of cognitive and functional decline among those with MCI or dementia that is clinically less typical of early AD, thus leading to etiologic uncertainty.

objectiveWe aimed to investigate whether elevated Aβ on PET scan predicts cognitive and functional decline over an 18-month period in those with MCI or dementia of uncertain etiology.

methodsIn 1,028 individuals with MCI or dementia of uncertain etiology, we evaluated the association between elevated Aβ on PET scan and change on a telephone cognitive status measure administered to the participant and change in everyday function as reported by their care partner.

resultsIndividuals with either MCI or dementia and elevated Aβ (66.6% of the sample) showed greater cognitive decline compared to those without elevated Aβ on PET scan, whose cognition was relatively stable over 18 months. Those with either MCI or dementia and elevated Aβ were also reported to have greater functional decline compared to those without elevated Aβ, even though the latter group showed significant care partner-reported functional decline over time.

conclusionsElevated Aβ on PET scan can be helpful in predicting rates of both cognitive and functional decline, even among cognitively impaired individuals with atypical presentations of AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesCognitionHumansPositron-Emission TomographyUncertaintyAmyloid beta-PeptidesActivities of daily livingAlzheimer’s diseaseamyloid-βcognitive declinedementiafunctional statusmild cognitive impairmentpositron emission tomography

Identifiers

PMID38306055
PMCPMC11034799
OpenAlexW4391346201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.